Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/8/2019
SIETES contiene 92796 citas

 
 
 1 a 20 de 670 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
van Eijk AM, Zulaika G, Lenchner M, Mason L, Sivakami M, Nyothach E, Unger H, Laserson KFPhillips-Howard PA. Menstrual cup use, leakage, acceptability, safety, and availability: a systematic review and meta-analysis. The Lancet Public Health 2019;4:1. [Ref.ID 103161]
3.Enlace a cita original Cita con resumen
5. Cita con resumen
Thielking M. FDA cracks down on ‘vaginal rejuvenation’ devices, citing potential for serious harm. STAT Daily Recap 2018:30 de julio. [Ref.ID 102728]
6. Cita con resumen
Anónimo. Bayer to halt sales of Essure at the end of the year. DIA Daily 2018:23 de julio. [Ref.ID 102719]
7.Enlace a cita originalTiene citas relacionadas Cita con resumen
Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, Basile J, Kirtane AJ, Wang Y, Lobo MD, Saxena M, Feyz L, Rader F, Lurz P, Sayer J, Sapoval M, Levy T, Sanghvi K, Abraham J, Sharp ASP, Fisher NDL, Bloch MJ, Reeve-Stoffer H, Coleman L, Mullin C, Mauri L, on behalf of the RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018;391:2335-45. [Ref.ID 102691]
9. Cita con resumen
Casassus B. Contraception implant removed from global market. Lancet 2017;390:1576. [Ref.ID 102079]
10. Cita con resumen
13. Cita con resumen
Golder S , Loke YK , Wright K , Norman G. ) Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review . PLOS Medicine 2016;13:e1002127. [Ref.ID 100696]
14. Cita con resumen
Mol GC, van de Ree MA, Flok FA, Tegelberg MJAM, Sanders FBM, Koppen S, de Weerdt O, Koster T, Hovens MMC, Kaasjager HAH, Brouwer RE, Kragten E, Schaar CG, Spiering W, Arnold WP, Biesma DH, Huisman MV. One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. BMJ 2016;353:i2691. [Ref.ID 100418]
16.Tiene citas relacionadas Cita con resumen
Anónimo. Zecuity (sumatriptan) migraine patch: Drug Safety Communication - FDA evaluating risk of burns and scars. U.S. Food and Drug Administration 2016:2 de junio. [Ref.ID 100357]
17. Cita con resumen
Anónimo. Implications of religious and cultural beliefs on selection of medicines. Drug Ther Bull 2016;54:45-8. [Ref.ID 100172]
18. Cita con resumen
Cohen D. Rivaroxaban: can we trust the evidence?. BMJ 2016;352:i575. [Ref.ID 100048]
20. Cita con resumen
Stam-Slob MC, Lambalk CB, van de Ree MA. Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ 2015;351:h4847. [Ref.ID 99595]
Seleccionar todas
 
 1 a 20 de 670 siguiente >>